-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
Orphan drugs, also known as rare disease drugs, refer to drugs used for the prevention, treatment and diagnosis of rare diseases
Lung cancer is currently the second most common malignant tumor in the world in terms of morbidity and mortality1
Currently, Junshi Biosciences is conducting a registrational clinical study for small cell lung cancer, the JUPITER-08 study (NCT04012606), and has completed the enrollment of subjects
"Currently, there are significant differences
Toripalimab was independently developed by Junshi Bio and has completely independent intellectual property rights worldwide.
references
- Cao Maomao, Chen Wanqing.
Toripalimab injection (Tuoyi® ) , as the first domestically produced monoclonal antibody targeting PD-1 approved for marketing in China, has been supported by major national science and technology special projects and won the highest award in the national patent field "China Patent Gold Award"
In March 2021, toripalimab was included in the Breakthrough Therapy Drug Program by the NMPA for the first-line treatment of advanced mucosal melanoma
Toripalimab started clinical research and development in early 2016.
About Junshi Bio
Junshi Bio (688180.
Relying on the core platform technology of protein engineering, Junshi Bio is at the forefront of international macromolecular drug research and development, and has obtained the first domestic anti-PD-1 monoclonal antibody NMPA marketing approval, domestic anti-PCSK9 monoclonal antibody NMPA clinical application approval, and the world's first anti-tumor anti-cancer drug.
Since the outbreak of the epidemic in 2020, Junshi has responded quickly, joined hands with domestic and foreign scientific research institutions and enterprises to fight the epidemic, and used technology accumulation to rapidly develop a variety of innovative drugs for the treatment of COVID-19, actively undertaking the social responsibility of Chinese pharmaceutical companies
At present, Junshi Bio has more than 2,800 employees worldwide, located in San Francisco and Maryland in the United States, and Shanghai, Suzhou, Beijing and Guangzhou in China
Official website:WeChat: Junshi Bio
